Karolinska Institute spinout Aprea Therapeutics has filed to raise approximately $68.3m in an IPO that will see it list on the Nasdaq Global Select Market.

Aprea Therapeutics, a US-based oncological drug developer spun out of Karolinska Institute, has filed for an initial public offering that it hopes will bring in nearly $68.3m in proceeds. A price range or timeline have not yet been set. Aprea plans to list on the Nasdaq Global Select Market under the ticker symbol APRE. Incorporated…

The rest of this content is only accessible to Global University Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.